Key result
Calycosin cuts myocardial collagen deposition ~44% and improves cardiac function in diabetic cardiomyopathy mice.
Why the study?
Impaired lipophagy is a key driver of diabetic cardiomyopathy (DCM), and calycosin (CA) exerts antidiabetic and cardioprotective effects. However, whether CA regulates lipophagy via Rab7a to ameliorate DCM remained largely unknown.
Does calycosin alleviate myocardial injury and lipid accumulation by enhancing Rab7a-mediated lipophagy in a mouse model of diabetic cardiomyopathy?
Does calycosin alleviate myocardial injury and lipid accumulation by enhancing Rab7a-mediated lipophagy in a mouse model of diabetic cardiomyopathy?
Calycosin ameliorates diabetic cardiomyopathy in preclinical models by inhibiting Rab7a ubiquitination and upregulating Rab7a-dependent lipophagy to clear toxic myocardial lipid droplets.
Calycosin improves cardiac function in diabetic cardiomyopathy mice; extends Rab7a lipophagy mechanisms but leaves clinical translation open.
Background Diabetic cardiomyopathy (DCM) is a major life-threatening cardiovascular complication of diabetes mellitus, characterized by myocardial lipid deposition, lipotoxicity and progressive cardiac dysfunction. Impaired lipophagy—the selective autophagic clearance of lipid droplets (LDs)—is a key driver of DCM progression, and Rab7a, a small GTPase, is essential for autophagosome–lysosome fusion, the rate-limiting step of efficient lipophagic degradation. Calycosin (CA), a natural isoflavone derived from Astragalus membranaceus , exerts antidiabetic and cardioprotective effects. However, whether CA regulates lipophagy via Ras-related protein Rab-7a (Rab7a) to ameliorate DCM remains largely unknown. The present study investigated whether CA alleviates DCM by promoting lipophagy through Rab7a-dependent mechanisms. Methods In vivo , DCM was induced in male C57BL/6J mice by a high-fat diet combined with low-dose streptozotocin (STZ), followed by daily CA administration. In vitro , neonatal mouse cardiomyocytes (NMCMs) were isolated and exposed to high glucose and high lipid (HGHL) conditions to mimic the DCM microenvironment. Cardiac function was assessed by echocardiography. Myocardial lipid accumulation was evaluated by Oi-Red O staining, Bodipy staining and triglyceride (TG) quantification assay. Lipophagy was monitored using transmission electron microscopy (TEM), LC3-LD colocalization analysis and Western blotting. Rab7a was knocked down in NMCMs using specific small interfering RNAs (siRNAs), and its ubiquitination level was detected by co-immunoprecipitation (Co-IP) assay. Results CA significantly improved cardiac function, reduced myocardial fibrosis and lipid accumulation, and restored impaired lipophagic flux in DCM mice. Consistently, in HGHL-stimulated NMCMs, CA promoted lipophagy and suppressed lipotoxic injury. Mechanistically, CA upregulated Rab7a protein expression and inhibited its ubiquitination. Rab7a knockdown abolished CA-mediated lipophagy activation and subsequent lipid clearance. Conclusion CA enhances cardiomyocyte lipophagy by upregulating Rab7a and suppressing its ubiquitination, thereby mitigating excessive lipid deposition and subsequent myocardial injury in DCM mice. These findings reveal a novel mechanism by which CA regulates cardiomyocyte lipophagy and highlight Rab7a-mediated lipophagy as a promising therapeutic target for diabetic cardiac lipotoxicity.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied Diabetic cardiomyopathy (DCM) (n=40). Calycosin vs. 0.9% normal saline vehicle control in vivo; untreated high glucose and high lipid (HGHL) or normal glucose (NG) control in vitro was evaluated on Myocardial interstitial collagen deposition, serum triglyceride levels, cardiac function (EF, FS, E/A ratio), and cardiomyocyte lipophagy (44.3% reduction in total myocardial collagen deposition and 31.6% reduction in serum triglycerides, p=<0.01). Calycosin reduced myocardial collagen deposition by 44.3% and serum triglycerides by 31.6% (p<0.01) while improving cardiac function and lipophagy via Rab7a in diabetic cardiomyopathy mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: